Anorectal Malformations Clinical Trial
Official title:
Sacral Neuromodulation for Constipation and Fecal Incontinence in Children and Adolescents - Randomized Controlled Trial on the Application of Invasive vs. Non-invasive Technique
The purpose of this study is to assess the efficacy of neuromodulation for treatment of chronic constipation and fecal incontinence in pediatric patients and to evaluate the differences between the invasive vs. non-invasive approach.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 2 Years to 17 Years |
Eligibility | Inclusion Criteria: - age between 2-17 years - informed consent - chronic constipation according to the ROME IV criteria for more than 3 months with or without encopresis/soiling despite underlying diseases such as slow-transit constipation, rectal evacuation disorders or Hirschsprung's disease. - refractory to conventional treatment in an appropriate weight-adapted application (training for bowel movements, lifestyle changes, pelvic floor training, pharmacological options) - in cases of Hirschsprung's disease: diagnosis confirmed histologically by rectal biopsies and in case of resection of an aganglionic segement: period between surgery and SNM at least 1 year - in cases of anorectal malformation or mechanical obstruction: post-surgical status: period between surgery and SNM at least 1 year Exclusion Criteria: - metabolic, inflammatory, and hormonal causes for chronic constipation - toxic megacolon or further emergencies, which must be treated surgically - sacral fractures or substantial differences in the sacral anatomy - inflammatory bowel disorders - rectal prolapse - neuronal malignancies under medical and radiation therapy - seizures |
Country | Name | City | State |
---|---|---|---|
Germany | Friedrich-Alexander-Universität Erlangen-Nürnberg, Pediatric Surgery | Erlangen | Bavaria |
Lead Sponsor | Collaborator |
---|---|
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of episodes of abdominal pain | Abdominal pain is recorded in number of episodes per week. Its intensity is evaluated via the numeric rating scale (0=no pain, 10=worst imaginable pain). Definition of success: reduction by at least 50% of episodes per week | Baseline and 12 and 24 weeks after start of therapy | |
Primary | Change of episodes of fecal incontinence | Number of episodes of fecal incontinence per week. Definition of success: reduction by at least 50% of episodes per week | Baseline and 12 and 24 weeks after start of therapy | |
Primary | Change of defecation frequency | Defecation frequency is measured by number of bowel movements per week. Definition of success: doubling of episodes per week to at least 3 or more bowel movements per week | Baseline and 12 and 24 weeks after start of therapy | |
Primary | Change of defecation consistency | Defecation consistency is measured daily by the Bristol Stool Scale, which classifies stool consistency from 1 (hard consistency) to 7 (fluid consistency). Definition of success: change of at least 2 points within the scale of 1-7 | Baseline and 12 and 24 weeks after start of therapy | |
Secondary | Change of proprioception | Improvement of proprioception is measured as mentioned in the specialized questionnaires. | Baseline and 12 and 24 weeks after start of therapy | |
Secondary | Episodes of urinary incontinence | The number of episodes per week is evaluated with the criterion for a clinically relevant improvement in cases of reduction by at least 50% of episodes per week. | Baseline and 12 and 24 weeks after start of therapy | |
Secondary | Change of Quality of Life | The quality of life is classified via the 'Revised Children's Quality of Life Questionnaire' (KINDLR). It consists of 24 5-point Likert-scale items, covering 6 quality of life dimensions: physical well-being, emotional well-being, self-esteem, family, friends and daily functioning (school or nursery school/kindergarten). Items are partially reverse scored and linearly transformed to a 0 to 100 scale according to the manual. Higher scores indicate a better quality of life. | Baseline and 12 and 24 weeks after start of therapy | |
Secondary | Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) | Adverse events are measured as mentioned in the specialized questionnaires: these include cutaneous reactions, urinary incontinence, dysfunction of stimulation or further unknown factors. | Baseline and 12 and 24 weeks after start of therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06065995 -
StoMakker Mobile Application
|
N/A | |
Completed |
NCT05621629 -
Management of FI After Surgery of ARM
|
||
Recruiting |
NCT05293353 -
Neokare Safety and Tolerability Assessment in Neonates With GI Problems
|
||
Recruiting |
NCT04904081 -
Feasibility of Use of Indocyanine Green in Pediatric Colorectal Surgery
|
Phase 3 | |
Not yet recruiting |
NCT05749406 -
Parental Attitudes to Neoanus Dilatations Post-reconstruction in Anorectal Malformations
|
||
Recruiting |
NCT05450991 -
Long-term Qualitative and Quantitative Outcomes of Children With Hirschsprung's Disease and Anorectal Malformations
|
||
Recruiting |
NCT06234020 -
Frequency of Vertebrospinal Anomalies in Patients Presenting With Anorectal Malformations
|
||
Completed |
NCT04901819 -
Longterm Outcomes of Individuals With Anorectal Malformations
|
||
Completed |
NCT04710433 -
Non-invasive Sacral Nerve Stimulation in Children and Adolescents With Chronic Constipation
|
N/A | |
Completed |
NCT05045560 -
Study of Antenatal and Postnatal Data of Anorectal Malformations Diagnosed at Montpellier University Hospital Over a 10-year Period (2010-2020)
|
||
Enrolling by invitation |
NCT04106947 -
Transition of Care for Patients With Hirschsprung Disease and Anorectal Malformations
|